RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BioXcel Therapeutics Stock

BioXcel Therapeutics Employees 2024

BioXcel Therapeutics Employees

50

Ticker

BTAI

ISIN

US09075P1057

WKN

A2JF20

In 2024, BioXcel Therapeutics employed 50 people, a 0% change from the 50 number of employees in the previous year.

BioXcel Therapeutics Aktienanalyse

What does BioXcel Therapeutics do?

BioXcel Therapeutics Inc. is a biotechnology company based in New Haven, CT, USA, focused on the development of novel therapeutics for severe neurological and psychiatric diseases as well as cancer. The company was founded in 2017 and is listed on the NASDAQ stock exchange. The founding of BioXcel Therapeutics Inc. was based on the concept that the combination of state-of-the-art data analytics technologies such as artificial intelligence (AI) and big data analysis with traditional biomedical approaches can open new opportunities in the field of drug discovery and development. The company utilizes its extensive database of clinical, genetic, molecular, and other data to identify targets and molecules that show promise for treating severe diseases. The business model of BioXcel Therapeutics Inc. includes both internal development and a licensing and partnership strategy. The company is working on various projects currently in different stages of clinical development. The key therapeutics currently in the company's pipeline include BXCL501, BXCL701, and BXCL702. BXCL501 is a novel treatment approach for acute anxiety and agitation in patients with schizophrenia, bipolar disorders, and Alzheimer's disease. The drug is based on a combination of DEX, an alpha-2 agonist, and melatonin. The company is currently planning a Phase III trial for BXCL501. BXCL701 is an oral immunoncology drug based on the inhibition of interleukin-12 and -23 and has the potential to treat various types of cancer. The drug is still in the clinical development phase. BXCL702 is a novel approach to treating pain in patients with peripheral neuropathic pain. The drug is currently in the preclinical development phase. BioXcel Therapeutics also operates a licensing and partnership strategy for drug development and commercialization. In November 2019, the company entered into an exclusive global licensing agreement with Nocion Therapeutics, a company specializing in the development of drugs for localized pain. Under this agreement, BioXcel Therapeutics will pursue the development and commercialization of Nocion's technology platform for the delivery of anesthetic drugs to patients with peripheral neuropathy. The company has also partnered with the Zambon Group, a leading European company in pharmaceutical and biotechnology research and development, and has entered into a research collaboration with Eisai Co. Ltd. BioXcel Therapeutics is an innovative company that combines the benefits of state-of-the-art data analytics technologies with traditional biomedical approaches to develop therapeutics for severe neurological and psychiatric diseases as well as cancer. The company has a well-stocked pipeline of promising drugs in various stages of clinical development and an effective licensing and partnership strategy that allows for further growth. BioXcel Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining BioXcel Therapeutics's Employee Base

BioXcel Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding BioXcel Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing BioXcel Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

BioXcel Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in BioXcel Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about BioXcel Therapeutics stock

How many employees does BioXcel Therapeutics have this year?

BioXcel Therapeutics has 50 undefined employees this year.

How many employees did BioXcel Therapeutics have compared to the previous year?

Compared to the previous year, BioXcel Therapeutics had 0% more employees.

What impact did the number of employees have on the company BioXcel Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of BioXcel Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of BioXcel Therapeutics?

The number of employees can also have an impact on investors of BioXcel Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of BioXcel Therapeutics affect the company?

An increase in equity of BioXcel Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in BioXcel Therapeutics's equity affect the company?

A reduction in equity of BioXcel Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of BioXcel Therapeutics?

Some factors that can influence the equity of BioXcel Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of BioXcel Therapeutics so important for investors?

The equity of BioXcel Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at BioXcel Therapeutics influence the company?

The number of employees at BioXcel Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at BioXcel Therapeutics evolved in recent years?

In recent years, the number of employees at BioXcel Therapeutics has changed by 0.

How many employees does BioXcel Therapeutics currently have?

BioXcel Therapeutics currently has 50 undefined employees.

Why is the number of employees important for investors of BioXcel Therapeutics?

The number of employees is important for investors of BioXcel Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can BioXcel Therapeutics take to change the number of employees?

To change the number of employees, BioXcel Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does BioXcel Therapeutics pay?

Over the past 12 months, BioXcel Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioXcel Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of BioXcel Therapeutics?

The current dividend yield of BioXcel Therapeutics is .

When does BioXcel Therapeutics pay dividends?

BioXcel Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioXcel Therapeutics?

BioXcel Therapeutics paid dividends every year for the past 0 years.

What is the dividend of BioXcel Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioXcel Therapeutics located?

BioXcel Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioXcel Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioXcel Therapeutics from 12/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did BioXcel Therapeutics pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of BioXcel Therapeutics in the year 2023?

In the year 2023, BioXcel Therapeutics distributed 0 USD as dividends.

In which currency does BioXcel Therapeutics pay out the dividend?

The dividends of BioXcel Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BioXcel Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von BioXcel Therapeutics

Our stock analysis for BioXcel Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioXcel Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.